表紙
市場調査レポート

爪真菌症:主要10カ国の市場予測

Onychomycosis Forecast in 10 Major Markets 2015-2025

発行 Black Swan Analysis 商品コード 339846
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
爪真菌症:主要10カ国の市場予測 Onychomycosis Forecast in 10 Major Markets 2015-2025
出版日: 2015年08月01日 ページ情報: 英文 44 Pages
概要

爪真菌症は、手先・足先の爪に発生する真菌感染症です。よく知られている病原体として、紅色白癬菌や毛瘡白癬菌といった菌類病原体が挙げられます。

当レポートでは、世界の主要10ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、ポーランド、ブラジル、日本、インド) における爪真菌症の発症状況について分析し、疾患の概要や現時点での有病者数、性別・年代別 (5歳区切り) の詳細状況、地域別・民族別傾向、リスク要因、疾患の診断と予後、主な症状や合併症、将来的な動向見通し (今後10年間分) といった情報を取りまとめてお届けいたします。

目次

  • 図表
  • 概要
  • イントロダクション
  • 疾患の原因
  • リスク要因と予防法
  • 疾患の診断
  • 地域別/民族別の差異
  • 疾患の予後と臨床経過
  • 疾患に関連する主な共存症/特徴
  • 患者数の定量化の手法
  • 爪真菌症の最大有病者数
  • 主な病原体
  • 疾患の平均持続期間
  • 疾患の重大な併発症
  • 感染症の主な徴候
  • 参考文献
  • 付録
目次
Product Code: ONYC0010815

Onychomycosis is a fungal infection of the nail which occurs in the hands or feet. The more notable causative agents include the fungal pathogens Trichophyton rubrum and Trichophyton mentagrophytes. This report provides the current prevalent population for Onychomycosis across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Poland, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors and prevention, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Onychomycosis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Onychomycosis include:

  • Tinea pedis infections
  • Diabetes
  • Peripheral vascular disease
  • HIV / AIDS
  • Hypercholesterolaemia
  • Osteoarticular disease
  • Psoriasis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Onychomycosis's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Onychomycosis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Useful in the identification and trend of the prevalence numbers for the different causative agents of Onychomycosis.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Onychomycosis's prevalent population.
  • Identify sub-populations within Onychomycosis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Onychomycosis patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR

Table of Contents

  • List of Tables & Figures
  • Overview
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Onychomycosis
  • Main Causative Agent
  • Average Duration of Disease
  • Significant Co-morbidities of Disease
  • Main Signs of Infection
  • References
  • Appendix

List of Tables & Figures

  • Prevalence of clinically diagnosed onychomycosis, total (000s)
  • Prevalence of clinically diagnosed onychomycosis, males (000s)
  • Prevalence of clinically diagnosed onychomycosis, females (000s)
  • Clinically diagnosed onychomycosis by type at presentation, total (000s)
  • Clinically diagnosed onychomycosis by site of infection, total (000s)
  • Clinically diagnosed onychomycosis by main type of fungal pathogen, total (000s)
  • Clinically diagnosed onychomycosis by average duration of disease, total (000s)
  • Clinically diagnosed onychomycosis patients with diabetes, total (000s)
  • Clinically diagnosed onychomycosis patients with tinea pedis, total (000s)
  • Clinically diagnosed onychomycosis patients with hyperkeratosis, total (000s)
  • Clinically diagnosed onychomycosis patients with onycholysis, total (000s)
  • Clinically diagnosed onychomycosis patients with paronychia, total (000s)
  • USA Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • USA Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • France Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • France Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Germany Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Germany Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Italy Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Italy Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Spain Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Spain Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Poland Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Poland Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Brazil Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Brazil Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • Japan Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • Japan Prevalence of onychomycosis by 5-yr age cohort, females (000s)
  • India Prevalence of onychomycosis by 5-yr age cohort, males (000s)
  • India Prevalence of onychomycosis by 5-yr age cohort, females (000s)
Back to Top